JPRN-UMIN000007318已完成2 期
Phase II clinical study of the combination chemotherapy regimen of topotecan plus oral etoposide for the treatment of recurrent ovarian cancer - Topotecan plus oral etoposide in recurrent ovarian cancer
Kyorin University, School of Medicine0 个研究点目标入组 20 人开始时间: 2012年2月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 79years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Patients with severe infectious disease and/or serious complication. 2) Patients who have severe gastrointestinal injury and/or gastrointestinal bleeding. 3) Patients who have necessary ascites and/or pleural effusion of measures. 4) Patients with interstitial pneumonia. 5) Patients with ileus. 6) Patients with active brain metastases. 7) Patients with active double cancer. 8) Patients who carried out bone marrow transplantation. 9) Patients who have the past of serious hypersensitivity. 10) Patients who are pregnant or who are at risk of pregnancy, or those who desire to become pregnant during their participation. 11) Patients who have uncontrolled diabetes mellitus. 12) Patients who received topoisomerase I inhibitor and/or topoisomerase II inhibitor containing chemotherapy within 6 months. 13) Inappropriate patients for this study judged by the physicians.
研究者
相似试验
已完成
2 期
A Phase II study of combination chemotherapy including Bortezomib in pediatric patients with relapsed acute lymphoblastic leukemia (Investigator-initiated clinical trial)A high-risk group of pediatric patients with first relapse of ALLor refractory ALL (patients who develop 2nd or subsequent relapse, relapse after hematopoietic cell transplantation or fail to achieve remission induction with one or more therapies).JPRN-UMIN000023815Department of Pediatric Oncology, National Cancer Center Hospital22
招募中
2 期
Multicenter phase II study of combination chemotherapy with IRIS and Cetuximab as second line therapy in patient with colorectal cancercolorectal cancerJPRN-UMIN000006793ippon Medical School Musashikosugi Hospital40
已完成
2 期
Phase II clinical trial of combination chemotherapy with bendamustine and rituximab for relapsed or refractory CD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma patientsCD20 positive indolent B-cell non-Hodgkin lymphoma and mantle cell lymphomaJPRN-UMIN000008024Kyoto University Hematology Study Group45
进行中（未招募）
不适用
Klinisk prövning med kombinationsbehandling av kemoterapi och antikroppar för behandling av patienter med gallgångscancer som inte kan opereras.EUCTR2010-020385-13-SEVejle Hospital78
进行中（未招募）
1 期
Randomized phase II trial of combination chemotherapy with panitumumab or bevacizumab for patients with inoperable cholangiocarcinoma without KRAS mutations - GOC-B-PEUCTR2010-020385-13-DKVejle Hospital